• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在注射毒品人群中检测丙型肝炎病毒感染的障碍和促进因素——定性证据的范围综述。

Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence.

机构信息

School of Pharmacy, Memorial University of Newfoundland, St. John's, Canada.

Health Sciences Library, Memorial University of Newfoundland, St. John's, Canada.

出版信息

BMC Public Health. 2023 Jun 1;23(1):1038. doi: 10.1186/s12889-023-16017-8.

DOI:10.1186/s12889-023-16017-8
PMID:37259073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10234098/
Abstract

BACKGROUND

Injection drug use is the primary mode of transmission of hepatitis C virus (HCV) infection in the developed world and guidelines recommend screening individuals with current or history of injection drug use for HCV; however, the majority of those living with HCV in Canada are not aware of their positive status. This low level of HCV status awareness suggests that screening is not effective with current testing strategies. The aim of this review is to determine what barriers and enablers people who inject drugs (PWID) experience surrounding testing for HCV to help inform the development of an engaging testing strategy.

METHODS

Comprehensive literature searches were conducted using Medline, Embase and CINAHL in February 2021. Included studies investigated the barriers and enablers to testing for HCV in PWID and the experiences of PWID in testing for HCV. Studies were included if they were qualitative or mixed-methods design, involved people with current injection drug use or those with a history of injecting drugs, and were written in the English language. Studies were compared and common themes were coded and analyzed.

RESULTS

The literature search resulted in 1554 citations and ultimately nine studies were included. Common barriers included self-perception of low risk for HCV, fear of diagnosis, stigma associated with IV drug use and HCV, antipathy in relation to mainstream health care services, limited knowledge about HCV, lack of rapport with provider, lack of motivation or competing priority of drug use, and limited awareness of new treatment options. Common enablers to testing included increasing awareness of HCV testing and treatment and providing positive narratives around HCV care, positive rapport with provider, accessible testing options and individualized care.

CONCLUSION

While there has been some qualitative research on barriers and enablers to testing for HCV in PWID more research is needed to focus on this research question as a primary objective in order to provide more understanding from the participant's perspective.

摘要

背景

在发达国家,注射毒品是丙型肝炎病毒 (HCV) 感染的主要传播途径,指南建议对当前或有注射毒品史的个体进行 HCV 筛查;然而,加拿大大多数 HCV 感染者并不知道自己的阳性状态。这种 HCV 知晓率低表明,目前的检测策略并不有效。本研究旨在确定注射毒品者 (PWID) 在 HCV 检测方面面临的障碍和促进因素,以帮助制定有吸引力的检测策略。

方法

2021 年 2 月,使用 Medline、Embase 和 CINAHL 进行了全面的文献检索。纳入的研究调查了 PWID 进行 HCV 检测的障碍和促进因素,以及 PWID 进行 HCV 检测的经验。如果研究是定性或混合方法设计,涉及当前使用注射毒品者或有注射毒品史者,且用英文书写,则纳入研究。对研究进行比较,并对共同主题进行编码和分析。

结果

文献检索产生了 1554 条引文,最终纳入了 9 项研究。常见障碍包括自我感知 HCV 风险低、害怕诊断、与 IV 药物使用和 HCV 相关的耻辱感、对主流医疗服务的反感、对 HCV 的了解有限、与提供者关系不佳、缺乏动力或吸毒的竞争优先事项,以及对新的治疗选择的认识有限。常见的检测促进因素包括提高对 HCV 检测和治疗的认识,提供 HCV 护理的积极叙述,与提供者建立良好的关系,提供便捷的检测选择和个性化的护理。

结论

虽然已经有一些关于 PWID 进行 HCV 检测的障碍和促进因素的定性研究,但需要更多的研究将这一研究问题作为主要目标进行重点关注,以便从参与者的角度提供更多的理解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/10234098/04ea11a3cd57/12889_2023_16017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/10234098/04ea11a3cd57/12889_2023_16017_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a8b/10234098/04ea11a3cd57/12889_2023_16017_Fig1_HTML.jpg

相似文献

1
Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence.在注射毒品人群中检测丙型肝炎病毒感染的障碍和促进因素——定性证据的范围综述。
BMC Public Health. 2023 Jun 1;23(1):1038. doi: 10.1186/s12889-023-16017-8.
2
Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis.调查英格兰、威尔士和北爱尔兰注射吸毒者中与丙型肝炎病毒检测相关的社会人口学和行为因素:一项定量横断面分析。
Int J Drug Policy. 2022 Nov;109:103821. doi: 10.1016/j.drugpo.2022.103821. Epub 2022 Aug 20.
3
Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research.吸毒人群对丙型肝炎检测和诊断的看法和体验:定性研究的系统评价。
Int J Drug Policy. 2014 Mar;25(2):204-11. doi: 10.1016/j.drugpo.2013.11.004. Epub 2013 Nov 21.
4
Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.干预措施以提高注射毒品者丙型肝炎感染的检测和治疗关联:系统评价和荟萃分析。
Int J Drug Policy. 2023 Jan;111:103917. doi: 10.1016/j.drugpo.2022.103917. Epub 2022 Dec 19.
5
'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.“全面治疗我这个人,而不仅仅是我的病情”:注射吸毒者的丙型肝炎护理提供偏好的定性探索。
Addict Sci Clin Pract. 2021 Aug 12;16(1):52. doi: 10.1186/s13722-021-00260-8.
6
Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.加拿大注射毒品的艾滋病毒-丙型肝炎病毒合并感染者在丙型肝炎病毒预防和护理方面存在的差距。
Int J Drug Policy. 2022 May;103:103627. doi: 10.1016/j.drugpo.2022.103627. Epub 2022 Feb 24.
7
Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan.吉尔吉斯斯坦注射吸毒者对丙型肝炎自我检测的价值观和偏好。
BMC Infect Dis. 2021 Jun 26;21(1):609. doi: 10.1186/s12879-021-06332-z.
8
Barriers and motivators to participation and retention in HIV/HCV cohort studies among people who inject drugs: a community consultation in Iran.在伊朗的一次社区咨询中,探讨了影响注射吸毒人群参与和保留 HIV/HCV 队列研究的障碍和促进因素。
Subst Abuse Treat Prev Policy. 2020 Aug 5;15(1):56. doi: 10.1186/s13011-020-00298-y.
9
Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.在普遍使用直接抗病毒药物治疗背景下注射吸毒者中丙型肝炎病毒感染状况的知晓情况:ETHOS 参与研究。
Int J Drug Policy. 2022 Dec;110:103876. doi: 10.1016/j.drugpo.2022.103876. Epub 2022 Oct 12.
10
Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.加利福尼亚州中部注射吸毒人群丙型肝炎抗体流行率、相关因素及影响治疗的因素分析。
J Viral Hepat. 2022 Jul;29(7):518-528. doi: 10.1111/jvh.13677. Epub 2022 Apr 6.

引用本文的文献

1
Experiences of people who inject drugs with hepatitis C testing and their perceptions of a pharmacy-based testing option: a qualitative study.注射吸毒者进行丙型肝炎检测的经历及其对基于药房的检测选项的看法:一项定性研究。
Int J Clin Pharm. 2025 Aug 29. doi: 10.1007/s11096-025-01986-0.
2
Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology.优先消除病毒性肝炎以预防肝细胞癌:有效预防肝病学的公共卫生方法。
JHEP Rep. 2025 May 2;7(8):101436. doi: 10.1016/j.jhepr.2025.101436. eCollection 2025 Aug.
3
Hepatitis C Testing in the US Veterans Health Administration: Uptake of United States Preventive Services Taskforce Universal Hepatitis C Screening Guidance.

本文引用的文献

1
The role of community pharmacies in the HIV and HCV care continuum.社区药房在艾滋病毒和丙型肝炎护理连续过程中的作用。
Explor Res Clin Soc Pharm. 2023 Jan 11;9:100215. doi: 10.1016/j.rcsop.2022.100215. eCollection 2023 Mar.
2
Implementation and Evaluation of a Collaborative, Pharmacy-Based Hepatitis C and HIV Screening Program.实施和评估一个协作型、以药房为基础的丙型肝炎和 HIV 筛查计划。
Prev Chronic Dis. 2022 Dec 8;19:E83. doi: 10.5888/pcd19.220129.
3
Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020.
美国退伍军人健康管理局的丙型肝炎检测:美国预防服务工作组丙型肝炎普遍筛查指南的采用情况
Open Forum Infect Dis. 2025 May 16;12(5):ofaf249. doi: 10.1093/ofid/ofaf249. eCollection 2025 May.
4
Gender-based factors associated with hepatitis C testing in people who inject drugs: results from the French COSINUS cohort.注射吸毒人群中与丙型肝炎检测相关的性别因素:来自法国COSINUS队列的结果。
BMJ Open. 2025 Mar 24;15(3):e091707. doi: 10.1136/bmjopen-2024-091707.
5
Scaling up hepatitis C testing and linkage-to-care among people who use drugs: lessons learned from a pilot project implemented at a supervised consumption site.扩大吸毒者中丙型肝炎检测及治疗衔接工作:从在一个受监管的消费场所实施的试点项目中吸取的经验教训。
BMC Health Serv Res. 2025 Feb 13;25(1):243. doi: 10.1186/s12913-025-12374-9.
6
Addressing viral hepatitis C reinfections in a low-threshold programme for people who inject drugs in Slovenia.在斯洛文尼亚针对注射吸毒者的低门槛项目中应对丙型病毒性肝炎再感染问题。
Harm Reduct J. 2025 Feb 13;22(1):16. doi: 10.1186/s12954-025-01164-5.
7
Implementing a new HCV model of care for people who use drugs.为吸毒者实施一种新的丙型肝炎护理模式。
JHEP Rep. 2024 Jun 13;6(10):101145. doi: 10.1016/j.jhepr.2024.101145. eCollection 2024 Oct.
8
Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs.对注射毒品者丙型肝炎治疗的认知和态度。
Harm Reduct J. 2024 Aug 28;21(1):160. doi: 10.1186/s12954-024-01068-w.
9
Subspecialty physicians' perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study.亚专科医生对丙型肝炎治疗障碍和促进因素的看法:一项定性研究。
Harm Reduct J. 2024 Jul 25;21(1):140. doi: 10.1186/s12954-024-01057-z.
10
Hepatitis C-related knowledge and attitude among adults on probation in a large US city.美国一个大城市中缓刑期成年人对丙型肝炎的相关知识与态度
Health Justice. 2024 Jul 11;12(1):30. doi: 10.1186/s40352-024-00287-4.
生命体征:2019-2020 年美国参保成年人中的丙型肝炎治疗。
MMWR Morb Mortal Wkly Rep. 2022 Aug 12;71(32):1011-1017. doi: 10.15585/mmwr.mm7132e1.
4
Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review.即时检测或干血斑样本检测丙型肝炎病毒 RNA 的诊断准确性:系统评价。
J Infect Dis. 2022 Sep 21;226(6):1005-1021. doi: 10.1093/infdis/jiac049.
5
Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.高收入国家优先人群中直接作用抗病毒药物治疗丙型肝炎的患者和提供者感知障碍及促进因素:知识综合。
Int J Drug Policy. 2021 Oct;96:103247. doi: 10.1016/j.drugpo.2021.103247. Epub 2021 Apr 11.
6
Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration.基于网络的丙型肝炎检测和治疗招募在注射毒品者中的认知:定性探讨。
Int J Drug Policy. 2021 Feb;88:103019. doi: 10.1016/j.drugpo.2020.103019. Epub 2020 Nov 4.
7
Engagement in the Hepatitis C care continuum among people who use drugs.吸毒者在丙型肝炎治疗连续过程中的参与情况。
J Subst Use. 2020;25(4):343-349. doi: 10.1080/14659891.2019.1704076. Epub 2020 Jan 1.
8
Progress towards elimination goals for viral hepatitis.迈向消除病毒性肝炎目标的进展。
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):533-542. doi: 10.1038/s41575-020-0332-6. Epub 2020 Jul 23.
9
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.药师主导与常规提供的抗病毒治疗在接受阿片类药物替代治疗的丙型肝炎病毒患者中的临床效果:一项实用的、集群随机试验。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):809-818. doi: 10.1016/S2468-1253(20)30120-5. Epub 2020 Jun 8.
10
Expanding access to HIV testing through Canadian community pharmacies: findings from the APPROACH study.通过加拿大社区药店扩大艾滋病毒检测服务的覆盖面:来自 APPROACH 研究的发现。
BMC Public Health. 2020 May 7;20(1):639. doi: 10.1186/s12889-020-08719-0.